

Dr. Gene Morse

Pharmacy Practice

*Associate Dean of Clinical and Translational Research, Professor*

School of Pharmacy and Pharmaceutical Sciences Department of Pharmacy Practice

Buffalo NY 14260-1200

Phone: (716) 645-2828 x252

Fax: (716) 645-2886

Email: [emorse@buffalo.edu](mailto:emorse@buffalo.edu)

Education:

- 1984 Fellowship in Clinical Pharmacokinetics  
The State University of New York at Buffalo
- 1983 Doctor of Pharmacy  
The State University of New York at Buffalo
- 1981 Residency in Hospital Pharmacy  
Moses Cone Memorial Hospital
- 1980 Bachelor of Science in Pharmacy  
The State University of New York at Buffalo
- 1976 Bachelor of Science in Biology  
The State University of New York at Albany
- 1974 Associate of Applied Science  
Nassau Community College

List of Publications: [\[click to see more\]](#)

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM; [Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.](#) Drug Alcohol Depend; 2007 Dec; 91(2-3) 269-278

Ma Q, Forrest A, Rosenkranz SL, Para MF, Yarasheski KE, Reichman RC, Morse GD; [Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.](#) Biopharm Drug Dispos; 2007 Nov; 29(2) 91-101

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD; [Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.](#) Am J Addict; 2007 Nov; 16(6) 488-494

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD; Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit; 2007 Oct; 29(5) 560-565

Ma Q, Brazeau D, Forrest A, Morse GD; Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics; 2007 Sep; 8(9) 1169-1178

DiFrancesco R, DiCenzo R, Vicente G, Donnelly J, Martin TM, Colon LA, Schifito G, Morse GD; Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal; 2007 Sep; 44(5) 1139-1146

Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD; Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic-pharmacodynamic analysis. Metab Syndr Relat Disord; 2007 Jun; 5(2) 163-173

Maponga CC, Ma Q, Slish JC, Morse GD; HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries. Top HIV Med; 2007 Jun; 15(3) 104-110

DiFrancesco R, Fischl MA, Donnelly J, Zingman BS, McCance-Katz EF, Moody DE, Reichman RC, Gripshover B, Morse GD; Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. J Pharm Biomed Anal; 2007 May; 44(1) 188-195

Okusanya O, Forrest A, DiFrancesco R, Bilic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD; Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother; 2007 May; 51(5) 1822-1826

McCabe SM, Smith PF, Ma Q, Morse GD; Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2) 197-207

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD; Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics; 2007 Mar; 8(3) 227-235

Keil K, Hochreitter J, DiFrancesco R, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Morse GD; Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit; 2007 Feb; 29(1) 103-109

Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD; Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials; 2007 Jan; 8(1) 19-23

McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM; Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis; 2006 Dec; 43 Su 235-246

McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM; Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis; 2006 Dec; 43 Su 224-234

Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD; Pharmacokinetic interactions between buprenorphine and

antiretroviral medications. Clin Infect Dis; 2006 Dec; 43 Su 216-223

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW; Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics; 2006 Nov; 16(11) 837-845

Keil, Kim, DiFrancesco R, Morse GD; Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array Ther Drug Monit; 2006 Aug; 28(4) 512-516

DiFrancesco R, Rosenkranz SL, Craft J, Morse GD; Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints. HIV Clin Trials; 2006 Jul; 7(4) 203-209

Holland DT, DiFrancesco R, Connor JD, Morse GD; Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring Ther Drug Monit; 2006 Jun; 28(3) 367-374

Martin TM, Morse GD, Kurpewski J, DiFrancesco R, Caliendo AM, Flanigan TP, Tashima KT; Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir AIDS; 2006 Apr; 20(7) 1085-1087

Catanzaro L, Morse GD, Acosta EP; Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy Lancet Infect Dis; 2006 Apr; 6(4) 215-225

Smith PF, Ogundele AB, DiFrancesco R, Berenson CS, Eberhardt E, Bednarczyk EM, Morse GD; Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers Pharmacotherapy; 2006 Mar; 26(3) 341-346

McCance-Katz EF, Rainey PM, Morse GD, Smith PF, Friedland G, Boyarsky B, Gourevitch M, Jatlow P.; Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine Am J Addict; 2006 Feb; 15(1) 23-34

Ma Q, Brazeau DA, Zingman B, Reichman RC, Fischl MA, Gripshover B, Venuto C, Slish JC, DiFrancesco R, Forrest A, Morse GD; Detection of MDR1 single nucleotide polymorphisms in HIV-infected substance users and nonusers Clinical Pharmacology & Therapeutics; 2006 Jan; 79 P67-P67

Slish JC, Catanzaro L, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD; Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring Curr Pharm Des; 2006 Jan; 12(9) 1129-1145

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB; Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study J Infect Dis; 2005 Dec; 192(11) 1931-1942

Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD; Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3) 473-485

Ma Q, Okusanya OO, Smith PF, DiCenzo R, Slish JC, Catanzaro L, Forrest A, Morse GD; Pharmacokinetic Drug Interactions with Non-Nucleoside Reverse Transcriptase Inhibitors Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3) 473-485

Morse GD, Rosenkranz S, Para MF, Segal Y, DiFrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC; Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother; 2005 Aug; 49(8) 3373-3381

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors Antimicrob Agents Chemother; 2005 Aug; 49(8) 3558-3561

Morse GD, Rosenkranz S, Para MF, Segal Y, DiFrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC; Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals Antimicrob Agents Chemother; 2005 Aug; 49(8) 3373-3381

Morse GD, Catanzaro L; Data from clinical trials J Acquir Immune Defic Syndr; 2005 Mar; 38 Su 26-29

Catanzaro LM, Morse GD; Data from clinical trials. J Acquir Immune Defic Syndr; 2005 Mar; 38 Su 26-29

Smith PF, DiCenzo R, Forrest A, Shelton MJ, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD, ACTG 260 Protocol Team, ACTG 261 Protocol Team; Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals Clin Pharmacokinetics; 2005 Jan; 44(1) 99-109

Smith PF, Diczno R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD; Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet; 2005 Jan; 44(1) 99-109

Catanzaro L, Morse GD; Fertility regulation and systemic hormones in HIV-infected and at-risk women: data from clinical trials Journal of Acquired Immune Deficiency Syndrome; 2005 Jan; 38(1) S26-S29

McCance-Katz EF, Rainey P, Smith PF, Morse GD, Friedland G, Boyarski B, Gourevitch M, Jatlow P; Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine American Journal of Addictions; 2005 Jan

Sligh JC, Catanzaro L, Ma Q, Okusanya OO, Demeter LM, Albrecht M, DiFrancesco R, Morse GD; Therapeutic Drug Monitoring: Role for a Pharmacist in a Multidisciplinary Antiretroviral Management Journal of Pharmacy Practice; 2005 Jan; 18(4) 310-321

Catanzaro L, Pollard RB, Shafer R, Sligh JC, Alkebulan AD, Morse GD; Antiretroviral Agents: Lamivudine, Emtricitabine In Antimicrobial Therapy and Vaccines Volume II; Antimicrobial Agents, Baltimore: Williams and Wilkins. 2005. Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD.(Ed/s.); 2005 Jan

Labbe L, Morse GD, Fischl MA, Feinberg J, Collier A, DiCenzo R, Sheiner LB; Effect of co-administration of efavirenz and nelfinavir on the pharmacokinetics of indinavir. Clinical Pharmacology and Therapeutics; 2005 Jan; 77(2) P80-P80

DiFrancesco R, Holland D T, Schiffhauer JE, Robbins BL, Tooley KM, Morse GD; A quality assurance program for AIDS clinical trials group pharmacology studies Qual Assur J; 2005 Jan; 44(1) 99-109

Catanzaro L, Morse GD; Drug Interaction between HAART and Oral Contraceptives: Data from clinical trials J Acquir Immune Defic Syndr; 2005 Jan; 38(Supp1) S26-S29

Pelham WE, Manos MJ, Ezzell CE, Tresco KE, Gnagy EM, Hoffman MT, Onyango AN, Fabiano GA, Lopez-Williams A, Wymbs BT, Caserta D, Chronis AM, Burrows-Maclean L, Morse GD; A dose-ranging study of a methylphenidate Transdermal system in children with ADHD J. Am. Acad. Child Adolesc. Psychiatry; 2005 Jan; 44(6) 522-529

Ma Q, Forrest A, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD; Optimal multi-drug PK sampling strategies (OSS) for efavirenz (EFV) & indinavir (IDV) Clinical Pharmacology & Therapeutics; 2005 Jan; 77 P42-P42

Zack YZ, Forrest A, Ma Q, Rosenkranz S, Para MF, Adams E, Reichman RC, Yarasheski K, Morse GD; Optimal sparse pharmacokinetic (PK) sampling strategies (OSS) for multi-drug antiretroviral (ARV) regimens Clinical Pharmacology & Therapeutics; 2005 Jan; 77 P90-P90

Pade P, Exhem-Williams C, Hellew L, Rainey PM, DiFrancesco R, Smith P, Morse GD, McCance-Katz EF; Buprenorphine does not alter efavirenz pharmacokinetics Drug and Alcohol Dependence; 2005 Jan

Catanzaro L, Pollard R, Shafer R, Slish J, Alkebulan A, Morse GD; Protease Inhibitors In Antimicrobial Therapy and Vaccines Volume II: Antimicrobial Agents, Baltimore: Williams and Wilkins, 2005. Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD. (Ed/s.); 2005 Jan

DiCenzo R, Peterson D, Cruttenden K, Morse G, Gelhard G, Schifitto G; Effects of Valproic Acid Coadministration on Efavirenz and Lopinavir/ritonavir Plasma Concentration in HIV-infected Adults Antimicrobial Agents and Chemotherapy; 2004 Nov; 48(11) 4328-4331

DiCenzo R, Predko L, Chen A, Wang L, Morris M, Frerichs V, Morse GD, DiCenzo R; The effects of quercetin on the plasma and intracellular concentrations (IC) of saquinavir (SQV) ; 2004 Nov

Ma Q, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Pharmacokinetic Interaction Studies of Efavirenz and Protease Inhibitors in HIV-Seronegative Volunteers ; 2004 Nov

Ma Q, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Pharmacokinetic Interaction Studies of Efavirenz and Protease Inhibitors in HIV-Seronegative Volunteers. ; 2004 Nov

Okusanya OO, Forrest A, Para, MF, Adams E, Yarasheski KE, Rosenkranz S, Reichman RC, Morse GD; Compartmental Analysis of Amprenavir Pharmacokinetics including Secondary Peaks. - Dallas, TX ; 2004 Oct

Ma Q, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD; Optimal sampling strategies (OSS) for sparse PK evaluation of multi-drug anti-HIV regimens ; 2004 Oct

Okusanya OO, Ma Q, Forrest A, Rosenkranz S, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Optimal Sampling Strategies for Sparse, Efficient PK Evaluation of Multi-drug HIV Regimens - Phoenix, AZ ; 2004 Oct

Okusanya OO, Forrest A, Rosenkranz S, Para MF, Para E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Compartmental Analysis of Amprenavir Pharmacokinetics Including Secondary Peaks - Phoenix, AZ ; 2004 Oct

Okusanya OO, Forrest A, Rosenkranz S, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Compartmental Analysis of Amprenavir Pharmacokinetics Including Secondary Peaks ; 2004 Aug

Ma Q, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Optimal Sampling Strategies for Sparse, Efficient PK Evaluation of Multi-drug HIV Regimens ; 2004 Aug

Ma Q, Forrest A, Okusanya OO, Rosenkranz S, Para MF, Adams E, Yarasheski K, Reichman RC, Morse GD, AACTG A5043 Protocol Team; Optimal Sampling Strategies for Sparse, Efficient PK Evaluation of Multi-drug HIV Regimens. ; 2004 Aug

Catanzaro LM, Slish JC, DiCenzo R, Morse GD; Drug interactions with antiretrovirals. Curr HIV/AIDS Rep; 2004 Jun; 1(2) 89-96

Slish JC, Catanzaro L, Esch L, DiFrancesco R, Hewitt R, Morse GD; Clinical Application of Therapeutic Drug Monitoring Alone and

Combined with Phenotypic Resistance Testing of Antiretrovirals. ; 2004 Apr

DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaldo H, DiFrancesco R, Morse GD, ACTG 388/733/5060 Study Team; Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naïve, HIV-Infected Subjects Antimicrobial Agent Chemother; 2004 Mar; 48(3) 918-923

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD, Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group; Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories Antimicrob Agents Chemother; 2004 Mar; 48(3) 824-831

DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaldo H, DiFrancesco R, Morse GD; Pharmacokinetics of indinavir and nelfinavir in treatment-naïve, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother; 2004 Mar; 48(3) 918-923

McCance-Katz EF, Rainey P, Smith P, Morse G, Friedland G, Boyarsky B, Gourevitch M, Jatlow P; Drug Interactions between opioids and antiretroviral medications: Interactions between methadone, LAAM, and nelfinavir Am J Addictions; 2004 Jan; 13 163-180

Catanzaro L, Alkebulan A, Morse GD; Nucleoside Analogs: Acyclovir, Penciclovir, Valaciclovir, and Famciclovir In Antimicrobial Chemotherapy, Williams & Wilkins, Baltimore, 2004, Editors: Yu V, Morse GD; 2004 Jan

Fischl MA, Catanzaro L, Morse GD; Nucleoside Analog Reverse Transcriptase Inhibitors (Zidovudine, Didanosine, Zalcitabine) In Antimicrobial Chemotherapy, Williams & Wilkins, Baltimore, 2004, Editors: Yu V, Morse GD; 2004 Jan

Catanzaro L, Pollard RB, Shafer R, Alkebulan A, Morse GD; Stavudine In Antimicrobial Chemotherapy, Williams & Wilkins, Baltimore, 2004, Editors: Yu V, Morse GD; 2004 Jan

Catanzaro L, Morse GD; Drug interactions between antiretrovirals HIV Medical Alert; 2004 Jan; 8(2)

Chen A, Forrest A, DiCenzo R, Rosenkranz S, Para MF, Yarasheski K, Reichman R, Morse GD, AACTG A5043 Protocol Team; A pharmacokinetic model for nelfinavir and M when coadministered with amprenavir and efavirenz. Pharmacotherapy; 2004 Jan; 24(10) 1461-1461

Catanzaro L, Slish JC, Esch (Swick) LD, DiFrancesco R, Maliszewski M, Hewitt RG, Morse GD; The Impact of an Adherence Program on Obtaining Interpretable Therapeutic Drug Monitoring of Antiretrovirals ; 2003 Dec

Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V, ACTG 372B/D Study Team; A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir Antivir Ther; 2003 Dec; 8(6) 507-518

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team; Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection N Engl J Med; 2003 Dec; 349(24) 2304-2315

Slish J, Catanzaro L, Esch LD, Lliguicota F, DiFrancesco R, Hewitt RG, Morse GD; Clinical application of therapeutic drug monitoring of antiretrovirals ; 2003 Nov

Fischl MA, Ribaldo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg

JE, Denter LM, Eshleman SH, Adult AIDS Clinical Trials Group 388 Study Team; A randomized trial of two different four-drug antiretroviral regimens versus a three-drug regimen, in advanced human immunodeficiency virus disease J Infect Dis; 2003 Sep; 188(5) 625-634

DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse GD; Coadministration of milk thistle and indinavir in healthy subjects Pharmacotherapy; 2003 Jul; 23(7) 866-870

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD, Adult AIDS Clinical Trials Group Protocol 368/886 Study Team; Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother; 2003 Jun; 47(6) 1929-1935

Keil K, Frerichs V, DiFrancesco R, Morse GD; Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit; 2003 Jun; 25(3) 340-346

Keil K, Frerichs VA, DiFrancesco R, Morse GD; Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit; 2003 Jun; 25(3) 340-346

Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD; Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother; 2003 May; 47(5) 1694-1699

Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S, Morse GD; Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother; 2003 May; 47(5) 1694-1699

Sligh JC, Catanzaro L, Esch (Swick) LD, Lliguicota FO, DiFrancesco R, Morse GD; HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry: Attaining Compliance With Clinical Laboratory Improvement Act (CLIA) and the Health Insurance Portability and Accountability Act (HIPAA) ; 2003 May

Frerichs VA, DiFrancesco R, Morse GD; Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Apr; 787(2) 393-403

Frerichs VA, DiFrancesco R, Morse GD; Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Apr; 787(2) 393-403

Maponga C, Simoyi M, Reichman RC, Esch (Swick) LD, Sligh JC, Morse GD; Promoting adherence to therapy using lay community volunteers: experience from urban Zimbabwe ; 2003 Mar

Sligh J, Catanzaro L, Esch LD, Lliguicota F, DiFrancesco R, Morse GD; HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry: Attaining compliance with Clinical Laboratory Improvement Act (CLIA) and Health Insurance Portability and Accountability Act (HIPAA) ; 2003 Mar

Maponga CC, Simoyi M, Esch (Swick) LD, Sligh JC, Hewitt RG, Reichman RC, Morse GD; Transitioning an Established Antiretroviral Adherence-Pharmacology Unit to Developing Countries ; 2003 Mar

Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD; Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J Clin Pharmacol; 2003 Feb; 43(2) 171-179

Shelton MJ, Hewitt RG, Adams JM, Cox SR, Chambers JH, Morse GD; Delavirdine malabsorption in HIV-infected subjects with

spontaneous gastric hypoacidity. J Clin Pharmacol; 2003 Feb; 43(2) 171-179

Smith PF, Robbins G, Shafer R, Wu H, Yu S, Hirsch M, Merigan T, Morse GD, ACTG 384 Study Team; Effect of Efavirenz on the Pharmacokinetics of Nelfinavir and M8 in Naïve, HIV-Infected Patients Receiving Long-Term HAART Therapy ; 2003 Feb

Holland D, DiFrancesco R, Hamzeh F, Morse G and the QA Subcommittee, AACTG Adult Pharmacology Committee; Antiretroviral Proficiency Testing Program for the Adult AIDS Clinical Trials Group (AACTG) Pharmacology Laboratory Network ; 2003 Feb

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW; Effect of food on the steady-state pharmacokinetics of delavirdine in patients with human immunodeficiency virus infection Clin Drug Investigation; 2003 Jan; 23(4) 255-261

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW; Effect of food on the steady-state pharmacokinetics of delavirdine in patients with human immunodeficiency virus infection. Clin Drug Investigation; 2003 Jan; 23(4) 255-261

Keil K, Frerichs V, DiFrancesco R, Morse GD; Reverse Phase High Performance Liquid Chromatography Method For the Analysis of Amprenavir, Efavirenz, Indinavir, Lopinavir, Nelfinavir and Its Active Metabolite, M8, Ritonavir, and Saquinavir in Heparinized Human Plasma Therapeutic Drug Monitoring; 2003 Jan; 25(3) 340-346

Morse GD, Cohn S, Shelton MJ, Greisberger C, Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC; Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients. Clin Drug Investigation; 2003 Jan; 23(5) 323-328

Maponga CC, Simoyi M, Esch (Swick) LD, Catanzaro L, Hewitt RG, Reichman RC, Morse GD; Transitioning an established Adherence-Pharmacology Unit to developing countries ; 2003 Jan

Morse GD, Fischl MA, Shelton MJ, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW; Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection. Clin Drug Investig; 2003 Jan; 23(4) 255-261

Booker BM, Smith PF, Morse GD; General Overview of Menstrual Cycle Physiology (Pages 1 - 2, 3 - 27); Sex Differences in Pharmacokinetics and Pharmacodynamics In Pharmacotherapy Self-Assessment Program,4th Edition; 2003 Jan

DiFrancesco R, Morse GD, Frerichs V; Determination of Protease Inhibitors Using Liquid Chromatography Coupled to Tandem Mass Spectrometry J. Chromtogr. B; 2003 Jan; 787 393-403

EF McCance-Katz, P Rainey, Morse GD, G Friedland, M Gourevitch, Smith P, P Jatlow; Drug Interactions between Opioids and Antiretroviral Medications I. Interaction between Methadone, LAAM, and Nelfinavir American Journal of Addiction; 2003 Jan

Booker B, Smith P, Morse, GD; Universal Precautions: Minimizing the Transmission of Blood-borne Pathogens to the Health Care Worker In Encyclopedia of Clinical Pharmacy - JT DiPiro, ed.; pages 891 - 898; Marcel Dekker, Inc.; 2002 Nov

Wisniewski A, Miklejn CA, Eppolito PA, Rossi M, Morse E; Integration of an Academic Pharmacy Initiative and Pharmacy Professional Experience Program with a Progressive Community Pharmacy Clinical Practice Program. ; 2002 Oct

Carlyn CJ, Baltch AL, St Clair M, Grembocki RA, George MJ, Bates M, Hellmann N, Morse GD, Becker MI, Smith RP; Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients ; 2002 Oct

Maponga C, Reichman RC, Esch LD, Hewitt RG, Morse GD; Global Pharmacotherapy Initiative Between Developed and Developing

Countries ; 2002 Apr

Frost CE, Adams J, Shelton M, Ebid A, Gugino LJ, Hewitt RG, DiFrancesco R, Ingalls E, Cousins S, Hu J, Morse GD; Indinavir Pharmacokinetics During Different Phases of the Menstrual Cycle in HIV-Infected Women Clin Drug Investigation; 2002 Jan; 22(2) 125-134

MORSE GD; Drug-Drug Interactions Between Pharmacotherapeutics Used in the Treatment of HIV/AIDS and/or Drug Addiction. JAMA; 2002 Jan

Frost CE, Adams J, Shelton M, Ebid AH, Gugino LJ, Hewitt RG, DiFrancesco R, Ingalls E, Cousins S, Hu J, Morse GD; Indinavir Pharmacokinetics During Different Phases of the Menstrual Cycle in HIV-Infected Women Clin Drug Investigation; 2002 Jan; 22(2) 125-134

Acosta EP, Gerber JG, Morse GD, Adult Pharmacology Committee of the AIDS Clinical Trials Group; Position Paper on Therapeutic Drug Monitoring of Antiretroviral Agents AIDS Res Human Retrovirus; 2002 Jan; 18(12) 825-834

Ferichs VA, Herrman, J, Colón, L.A, Morse GD; Capillary Electrophoresis for the Determination of Unbound Protease Inhibitors ; 2002 Jan

Tornatore KM, Garey KW, Saigal N, Reed K, Murray BM, Ingalls E, DiFrancesco R, Forrest A, Morse GD, Venuto RC, Morse GD; Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant; 2001 Oct; 15(5) 297-308

Booker BM, Smith PF, DiFrancesco R, Morse GD, Cottone PF, Murphy MK, McCance-Katz E; Lack of Effect of Methadone (MET) on the Pharmacokinetics (PK) of Delavirdine (DLV) & N-Delavirdine (NDLV). ; 2001 Sep

Smith PF, Booker BM, DiFrancesco R, Morse GD, Cottone PF, Murphy MK, McCance-Katz E; Effect of Methadone or LAAM on the Pharmacokinetics of Nelfinavir & M8. ; 2001 Sep

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrissey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fiebelkorn K, Fiebelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Morse GD; Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings Pediatrics; 2001 Jun; 107(6) E105-E105

Hardy H, Esch LD, Morse GD; Glucose Disorders Associated with HIV and Its Drug Therapy. Ann Pharmacother; 2001 Mar; 35(3) 343-351

Smith PF, Booker BM, DiFrancesco R, Morse GD, Friedland G, Boyarsky BK, Sarlo JA, Gourevitch M, Murphy MK, McCance-Katz EF; Nelfinavir (NFV) & M8 Pharmacokinetic Changes with Coadministration of Methadone (M) or LAAM (L). ; 2001 Mar

DiFrancesco R, Bartos L, Hewitt RG, Morse GD; High performance Liquid Chromatography Method for Simultaneous Measurement of Five Protease Inhibitors Plus Efavirenz ; 2001 Feb

Esch (Swick) LD, Hardy H, Wynn H, Shelton M, Hewitt RG, Morse GD; Intensive Adherence Interventions Improve Virologic Response to Antiretroviral Therapy (ART) in Treatment Naïve patients ; 2001 Feb

Dykes C, Fox K, Lloyd A, Chiulli M, Morse GD, Demeter LM; Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants Virology; 2001 Jan; 285 193-203

Ebid AH, Shelton MJ, Adams JM, Cordaro JA, Gugino LJ, Maliszewski M, Colomaio R, Hewitt RG, Morse GD; Menstrual Cycle and Zidovudine Pharmacokinetics in HIV-Infected Women Clin Drug Investig; 2001 Jan; 21 715-726

Lee CJ, Morse GD (Reviewer); Development and Evaluation of Dugs: From Laboratory through Licensure to Market - 2nd edition ; 2001 Jan

Smith PF, DiCenzo R, Morse GD; Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors Clin Pharmacokinet; 2001 Jan; 40(12) 893-905

Smith PF, DiCenzo R, Morse GD; Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet; 2001 Jan; 40(12) 893-905

Frerichs VA, DiFrancesco R, Morse GD, Colón, L.A; Pharmaceutical Analysis Through Implementation of Contemporary Methodology ; 2001 Jan

Shelton MJ, Akbari B, Hewitt RG, Adams JM, Morse GD; Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr; 2000 May; 24(1) 79-82

Shelton MJ, Akbari B, Ross Hewitt, Adams JM, Morse GD; Eradication of Helicobacter pylori is associated with increased exposure to delavirdine in hypochlorhydric HIV-positive patients. J Acquir Immune Defic Syndr; 2000 May; 24(1) 79-82

Magee MH, Forrest A, Shelton M, Para M, Fischl M, Morse GD; An Integrated PK/PD Model for Delavirdine Clinical Pharmacology & Therapeutics; 2000 Feb; 67(2) 162-162

MORSE GD Editors FISCHL M and MANDELL G; Drug Interactions with Antiretrovirals Curr Infect Dis Rep; 2000 Jan; 2000(2) 257-266

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D; Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res; 2000 Jan; 45(1) 47-58

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D, Morse ED; Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res; 2000 Jan; 45(1) 47-58

Smith PF, Morse GD; Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease. Ann Pharmacother; 1999 Dec; 33(12) 1329-1335

Smith PF, Morse GD; Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease Ann Pharmacother; 1999 Dec; 33(12) 1329-1335

Smith PF, Morse GD; Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease Ann Pharmacother; 1999 Dec; 33(12) 1329-1335

Esch LD, Hardy H, Shelton MJ, Hewitt RG, Morse GD; Adherence as a determinant of virologic response to highly active antiretroviral therapy ; 1999 Oct

Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M; Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm<sup>3</sup> (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr;

1999 Aug; 21(4) 281-292

Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW; ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrob Agents Chemother; 1999 Jun; 43(6) 1373-1378

Herman RA, Noormohamed S, Hirankarn S, Shelton MJ, Huang E, Morse GD, Hewitt RG, Stapleton JT; Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection. Pharmacotherapy; 1999 Jun; 19(6) 734-740

Herman RA, Noormohamed S, Hirankarn S, Shelton MJ, Huang E, Morse GD, Hewitt RG, Stapleton JT; Comparison of a neural network approach with five traditional methods for predicting creatinine clearance in patients with human immunodeficiency virus infection. Pharmacotherapy; 1999 Jun; 19(6) 734-740

Esch LD, Shelton MJ, Hewitt RG, Morse GD; Doctoral clerkship opportunities in a Pharm.D. operated medication adherence clinic in an ambulatory care HIV setting ; 1999 Apr

Esch LD, Shelton MJ, Hewitt RG, DiFrancesco R, Morse GD; Development of a therapeutic drug monitoring service for HIV protease inhibitors in an ambulatory care clinic. ; 1999 Jan

Squires K, Hammer S, Degruittola V, Fischl M, Grimes J, Demeter L, Morse G; Randomized trial of abacavir (ABC) in combination with indinavir (IDV) and efavirenz (EFV) in HIV-infected patients (pts) with nucleoside analog experience (NRTI exp) ; 1999 Jan 207-207

Kuritzkes DR, Marschner IC, Johnson VA, Bassett RL, Eron JJ, Bell DL, Wood K, Sommadossi JP, Morse GD, Pettinelli CB; Continued lamivudine (3TC) vs. delavirdine (DLV) in combination with indinavir (IDV) and zidovudine (ZDV) or stavudine (d4T) in 3TC-experienced patients ; 1999 Jan 159-159

Fischl MA, Morse GD; Zidovudine, Didanosine and Zalcitabine ; 1999 Jan

Bednarczyk EM, Ackerhalt R, Guarasci D, Morse GD; Medical imaging an underdeveloped area of pharmacy practice. Description of an approach to educational and clinical services ; 1999 Jan

Esch LD, Shelton MJ, Morse GD; Doctoral clerkship opportunities in a Pharm.D. candidate-operated medication adherence clinic in an ambulatory care HIV setting ; 1999 Jan

Esch LD, Shelton MJ, Hewitt RG, DiFrancesco R, Morse GD; Development of a therapeutic drug monitoring service for HIV protease inhibitors in an ambulatory care clinic ; 1999 Jan

Esch (Swick) LD, Shelton MJ, Hewitt RG, Morse GD; Pharmacologic and adherence factors complicating antiretroviral therapy for HIV ; 1999 Jan; 3(II) 483-496

Shelton MJ, Adams JM, Hewitt RG, Morse GD; Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin Infect Dis; 1998 Oct; 27(4) 739-745

Shelton MJ, Adams JM, Hewitt RG, Morse GD; Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin Infect Dis; 1998 Oct; 27(4) 739-745

Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone

J, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC; Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2) 135-144

Adams JM, Shelton MJ, Hewitt RG, Grasela TH, DeRemer M, Morse GD; Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother; 1998 Apr; 42(4) 821-826

Adams JM, Shelton MJ, Hewitt RG, Grasela TH, DeRemer M, Morse GD; Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother; 1998 Apr; 42(4) 821-826

Adams JM, Shelton MJ, Hewitt RG, DeRemer M, DiFrancesco R, Grasela TH, Morse GD; Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother; 1998 Feb; 42(2) 409-413

Adams J, Frost C, Shelton M, Gugino L, Hewitt RG, Steinwandel C, DiFrancesco R, Ingalls L, Cousins S, Morse GD; Indinavir pharmacokinetics and menstrual cycle physiology ; 1998 Jan

Shelton MJ, Hewitt RG, Adams JM, Baldwin J, Della-Coletta A, Cox S, Batts DH, Morse GD; Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir ; 1998 Jan

Shelton MJ, Hewitt RG, Adams JM, Forrest A, Morse GD; Helicobacter pylori serology, not ethnic group, is primary determinant of gastric pH in HIV+ subjects ; 1998 Jan

Saigal N, Venuto R, Tornatore KM, Garey K, Murray B, Forrest A, Ingalls E, DiFrancesco R, Reed K, Morse GD; Ganciclovir pharmacokinetics in renal transplant patients with cytomegalovirus infection ; 1997 Nov

Shelton MJ, Adams JM, Ross Hewitt, Steinwandel C, DeRemer M, Cousins S, Morse GD; Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine. Pharmacotherapy; 1997 Jun; 17(3) 438-444

DeRemer M, DiFrancesco R, Bartos L, Cousins S, Morse GD; Radioimmunoassay of zidovudine: extended use and potential application. Ther Drug Monit; 1997 Apr; 19(2) 195-200

Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC; HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2) 136-144

Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW, Morse ED; Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother; 1997 Jan; 41(1) 169-174

Khalilieh SG, Forrest A, Shelton M, Para M, Fischl M, Cox S, Friemuth WW, Morse G, ACTG 260 Protocol Team; Population Pharmacokinetics of Delavirdine and N-Delavirdine - Toronto ; 1997 Jan

Shelton MJ, Hewitt RG, Adams JA, Forrest A, Morse GD; Helicobacter pylori Serology, Not Ethnic Group, is the Primary Determinant of Gastric pH in HIV-Positive Patients. ; 1997 Jan

Saigal N, Venuto R, Tornatore KM, Garey K, Murray B, Forrest A, Ingalls E, DiFrancesco R, Reed K, Morse GD; Ganciclovir Pharmacokinetics in Renal Transplant Patients with Cytomegalovirus Infection. ; 1997 Jan

Khalilieh SG, Forrest A, Shelton M, Para M, Fischl M, Cox S, Friemuth WW, Morse GD, ACTG 260 Protocol Team.; Population Pharmacokinetics of Delavirdine and N-Delavirdine - Phoenix ; 1997 Jan

Swick L, Adams JM, Shelton MJ, Hewitt RG, Forrest A, Cox S, Friemuth WW, DiFrancesco R, Cousins S, Hu J, Ingalls E, Bartos, Morse GD; Exploratory Evaluation of the Relationship Between Cytokine Profiles and Delavirdine Concentrations in HIV-Infected Outpatients. ; 1997 Jan

Garey KW, Tornatore KM, Saigal N, Reed K, Venuto R, Murray B, Forrest A, Morse GD; Pharmacokinetics of Ganciclovir in Renal Transplant Recipients with Cytomegalovirus. ; 1997 Jan

Mudd P, Adams JM, Shelton MJ, Hewitt R, Forrest A, Cousins S, DiFrancesco R, Hu J, Morse GD; Eight Hour Plasma Cytokine Profiles in HIV-Infected Patients and Seronegative Controls. ; 1997 Jan

Mudd PM, Adams JM, Shelton MJ, Hewitt RG, Forrest A, Cousins S, DiFrancesco R, Hu J, Morse GD; Comparison of Plasma Cytokine Profiles Between HIV-Infected Patients and Seronegative Controls. (submitted) ; 1997 Jan

Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW; Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother; 1997 Jan; 41(1) 169-174

Shelton MJ, Adams JM, Hewitt R, Esch (Swick) L, Steinwandel C, Morse Gd; Antiretroviral use in the era of protease inhibitors ; 1997 Jan

Mudd PJ, Adams J, Shelton M, Hewitt RG, Cousins S, Hu J, D'Ambrosio R, Morse GD; Comparison of proinflammatory cytokine profiles between HIV+ patients and seronegative volunteers. ; 1997 Jan

Chaput AJ, D'Ambrosio R, Morse GD; In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res; 1996 Oct; 32(2) 81-89

Chaput AJ, DiFrancesco R, Morse GD; In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res; 1996 Oct; 32(2) 81-89

DeRemer M, D'Ambrosio R, Morse GD; Didanosine measurement by radioimmunoassay. Antimicrob Agents Chemother; 1996 Jun; 40(6) 1331-1334

Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M, Lee K, Wajszczuk CP, Morse ED; Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Antimicrob Agents Chemother; 1996 Mar; 40(3) 767-771

Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M, Lee K, Wajszczuk CP; Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections. Antimicrob Agents Chemother; 1996 Mar; 40(3) 767-771

Adams JM, Hu J, D'Ambrosio R, Morse GD; Interleukin-8 Assay validation and detection in HIV-infected patients ; 1996 Jan

Morse GD, Hu J, Ingalls E, Bartos L, D'Ambrosio R; In vitro studies of drug-drug protein binding displacement with delavirdine mesylate ; 1996 Jan

Para M, Morse GD, Fischl M, ACTG 260 Study Te; Plasma protein binding of delavirdine in HIV-infected patients in ACTG 260 ; 1996 Jan

Shelton MJ, Adams J, Hewitt R, Cox S, Chambers J, Freimuth W, Carberry P, Morse GD; Acidification strategies in HIV+ subjects with gastric hypoacidity ; 1996 Jan

Shelton M, Adams J, Gugino, Hewitt RG, Cordaro J, Cousins S, Morse GD; Menstrual cycle hormone patterns in HIV-infected women ; 1996 Jan

Morse GD, Adams J, Shelton M, Hu J, Hewitt RG, D'Ambrosio R; Clinical evaluation of cytokine profile switching in HIV+ patients ; 1996 Jan

Morse GD, Para M, Fischl M, Freimuth W; Concentration-targeted delavirdine therapy in 82 patients in ACTG 260 ; 1996 Jan

Para MF, Fischl M, Meehan P, Morse GD, Wood K, Shafer R, Freimuth W, Demeter L, Holden-Wiltse J, Nevin T for the ACTG 260 Study Team; Randomized phase I/II concentration-controlled trial of the anti-HIV activity of delavirdine ; 1996 Jan

Morse GD, Adams JM, Shelton MJ, Hewitt RG, Cox SR, Chambers JH; Gastric acidification increases DLV mesylate exposure in HIV+ subjects with gastric hypoacidity ; 1996 Jan

Morse GD, Adams JM, Shelton MJ, Hewitt RG, Cordaro JA; Lack of influence of menstrual cycle on zidovudine pharmacokinetics ; 1996 Jan

Shelton MJ, Adams JM, Hewitt RG, Morse GD; Reduced delavirdine exposure in HIV-positive subjects with gastric hypoacidity ; 1996 Jan

Shelton MJ, Adams JM, Hewitt RG, Morse GD; High frequency of Helicobacter pylori co-infection in HIV-positive subjects with gastric hypoacidity ; 1996 Jan

Shelton MJ, Adams JM, DiFrancesco R, DeRemer M, Hewitt RG, Grasela TH, Morse GD; Zalcitabine population pharmacokinetics in HIV-infected outpatients ; 1996 Jan

Morse GD, Adams JM, Shelton MJ, Hewitt RG, Cordaro JA; Lack of influence of menstrual cycle on zidovudine pharmacokinetics - ACCP Presentation ; 1996 Jan

Adams JM, Shelton MJ, Chiang H, Hewitt RG, Grasela TH, Fiedler-Kelly J, DeRemer R, Morse GD; Population pharmacokinetics of antiretrovirals Recent Res Devel in Antimicrob Agent Chemother; 1996 Jan; 1 371-380

Demeter L, Shafer R, Para M, Morse GD, Freimuth W, Merigan T, Reichman R; Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients (pts) receiving DLV monotherapy ; 1996 Jan 113-113

Shelton MJ, Adams JM, Hewitt RG, Morse GD; Reduced delavirdine exposure in HIV-positive subjects with gastric hypoacidity Pharmacother; 1996 Jan; 16(1) 40E-40E

Shelton MJ, Adams JM, Hewitt R, Morse G; High frequency of Helicobacter pylori co-infection in HIV-positive subjects with gastric hypoacidity Pharmacother; 1996 Jan; 16(1) 41E-41E

Shelton MJ, Adams JM, Hewitt R, DeRemer M, D'Ambrosio R, Grasela TH, Morse Gd; Zalcitabine population pharmacokinetics in HIV-infected outpatients Pharmacother; 1996 Jan; 16(1) 131-131

Morse Gd, Adams JM, Shelton MJ, Hewitt R, Cordaro JA; Lack of influence of menstrual cycle on zidovudine pharmacokinetics Clin Pharmacol Ther; 1996 Jan; 59(2) 147-147

Huang EL, Hewitt RG, Shelton MJ, Morse GD; Comparison of measured and estimated creatinine clearance in patients with

advanced HIV disease. Pharmacotherapy; 1996 Jan; 16(2) 222-229

Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC; Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis; 1995 Dec; 172(6) 1480-1485

Morse GD, Shelton MJ, Ho M, Bartos L, DeRemer M, Ragni M; Pharmacokinetics of zidovudine and didanosine during combination therapy. Antiviral Res; 1995 Aug; 27(4) 419-424

Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C, Nevin T, Wood K, Meehan PM, Geheb H, Cox S, Batts D, Timpone J, the ACTG 199 Study Team; Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. J Infect Dis; 1995 Feb; 171(2) 297-304

Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C; Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. J Infect Dis; 1995 Feb; 171(2) 297-304

Rosser L, O'Donnell AM, Lee K, Morse GD; Protein binding of atevirdine Antiviral Res; 1995 Jan 193-200

Morse GD, Fischl MA, Cox SR, Thompson L, Della-Coletta AA, Freimuth WW; Effect of food on the steady-state pharmacokinetics of delavirdine mesylate in HIV-positive patients ; 1995 Jan

Shelton M, Adams J, Hewitt RG, Cox S, Freimuth W, Chambers J, Morse GD; Reduced delavirdine exposure in HIV+ subjects with gastric hypoacidity ; 1995 Jan

Shelton MJ, Adams JM, Hewitt R, Morse GD; High frequency of Helicobacter pylori co-infection in HIV+ subjects with gastric hypoacidity ; 1995 Jan

Morse GD, Para M, Fischl M, Freimuth W, ACTG 260 Study Team; Delavirdine dosage requirements during a concentration-targeted study ; 1995 Jan

Chaput AJ, Morse GD; In vitro protein binding of delavirdine and its N-dealkylated metabolite ; 1995 Jan

Demeter L, Nawaz T, Morse GD, Dolin R, Reichman R; AZT resistant HIV-1 isolates obtained during ddl monotherapy from a patient with no history of AZT use ; 1995 Jan

Huang EL, Hewitt RG, Shelton M, Morse GD; Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease ; 1995 Jan

Adams JM, (Morse GD); Didanosine population pharmacokinetics Relationship between drug exposure and surrogate marker response. ; 1995 Jan

MORSE GD; Gastric hypoacidity among HIV-infected outpatients ; 1995 Jan

O'Donnell AM, Liu VJ, Cousins SP, Morse GD; Zidovudine recovery from phosphorylated anabolites under different experimental conditions using two types of alkaline phosphatase ; 1995 Jan

MORSE GD; Antiretroviral Therapy ; 1995 Jan

Morse GD, Shelton M, O'Donnell A; Treatment of HIV Infection ; 1995 Jan

Demeter LM, Shafer RW, Para M, Morse GD, Freimuth W, Merigan T; Delavirdine susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy (ACTG 260) ; 1995 Jan

Demeter LM, Gerondelis P, Dexter A, Berrios L, Morse GD, Cox S, Freimuth W, Reichman RC; Combination therapy with delavirdine and ddl, but not AZT, fails to prevent the emergence of Y181C in nucleoside experienced patients ; 1995 Jan

Rosser LM, O'Donnell AM, Lee KM, Morse GD; In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res; 1994 Dec; 25(3-4) 193-200

O'Donnell AL, Letting DJ, DeRemer MF, Morse GD; Evidence of alkaline phosphatase interference in a zidovudine radioimmunoassay. Antimicrob Agents Chemother; 1994 Dec; 38(12) 2689-2694

Rosser LM, O'Donnell AL, Lee KH, Morse GD; In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res; 1994 Dec; 25(3-4) 193-200

Shelton MJ, Portmore A, Blum MR, Sadler BM, Reichman RC, Morse GD; Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy; 1994 Nov; 14(6) 671-677

Foisy MM, Slayter KL, Hewitt RG, Morse GD; Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother; 1994 Sep; 28(9) 1025-1028

Haase EM, Yi K, Morse GD, Murphy TF; Mapping of bactericidal epitopes on the P2 porin protein of nontypeable Haemophilus influenzae. Infect Immun; 1994 Sep; 62(9) 3712-3722

Haase EM, Kyungcheol Yi, Morse G, Murphy TF; Mapping of bacterial epitopes on the P2 porin protein of nontypeable H. influenzae Infection Immunity; 1994 Sep; 62(9) 3712-3722

Foisy MM, Slayter KL, Ross Hewitt, Morse GD; Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother; 1994 Sep; 28(9) 1025-1028

Shelton MJ, Morse G, Portmore A, Blum MR, Sadler BM, Reichman RC; Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast Antiviral Res; 1994 Jan; 14(6) 671-677

Foisy MM, Slayter KL, Hewitt R, Morse GD; Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine Ann Pharmacother; 1994 Jan; 28 1025-1028

Freimuth B, Davey R, Batts D, Lane C, Cox S, Wathen L, Peel B, Daenzer C, Morse GD, Chaitt D, et al; Phase II clinical trials of delavirdine mesylate combination therapy ; 1994 Jan; 10(2) 59-59

Morse GD, Fischl MA, Cox SR, Driver MR, Freimuth WW; Effect of didanosine on single-dose pharmacokinetics of delavirdine ; 1994 Jan

Shelton MJ, Morse GD, Borin MT, Driver MR, Wajczczuk CP, DeRemer MF, Lee K, Fischl MA; Didanosine reduces atevirdine absorption ; 1994 Jan

Morse GD, Cox SR, DeRemer MF, Batts DH, Freimuth WW; Zidovudine pharmacokinetics during an escalating, multiple-dose study of delavirdine ; 1994 Jan

O'Donnell AM, Liu VJ, DeRemer MF, Morse GD; Recovery of zidovudine from mono-, di-, and triphosphate salts using two different alkaline phosphatases ; 1994 Jan

Reichman R, Demeter L, Fischl M, Hewitt R, Para M, Morse GD; Didanosine population pharmacokinetics among HIV-infected outpatients. Pharmacother; 1993 Dec 134-134

Karki SD, Bentley DW, Luzier A, Taylor C, Morse GD; Disposition of intramuscular cefonicid in elderly patients. J Am Geriatr Soc; 1993 Aug; 41(8) 808-810

Luzier A, Morse GD; Intravascular distribution of zidovudine: role of plasma proteins and whole blood components Antiviral Res; 1993 Jul; 21(3) 267-280

Luzier A, Morse GD; Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res; 1993 Jul; 21(3) 267-280

Luzier A, Morse GD, Morse ED; Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res; 1993 Jul; 21(3) 267-280

Cordaro JA, Morse G, Bartos L, Gugino LJ, Maliszewski M, Colomaio R, Shelton M, O'Donnell A, Hewitt R; Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle. Pharmacotherapy; 1993 Jul; 07(4) 369-377

Morse GD, Fischl M, Leedom J, Batts D, Cox S, Reichman R; Ateviridine (ATV) pharmacokinetics (PK) and dosage requirements during a concentration-targeted (CT) phase I study. (For ACTG Team 199) ; 1993 Jun; 9 477-477

Shelton MJ, O'Donnell AL, Morse GD; Zalcitabine. Ann Pharmacother; 1993 Apr; 27(4) 480-489

Hewitt RG, Morse GD, Lawrence WD, Maliszewski ML, Santora J, Bartos L, Bonnem E, Poiesz B; Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother; 1993 Mar; 37(3) 512-522

Hewitt R, Morse GD, Lawrence WD, Maliszewski ML, Santora J, Bartos L, Bonnem E, Poiesz B; Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother; 1993 Mar; 37(3) 512-522

Morse GD, Shelton MJ, O'Donnell AL; Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet; 1993 Feb; 24(2) 101-123

Adams J, Shelton M, Grasela T, Hewitt RG, DeRemer M, Morse GD; Prospective evaluation of zalcitabine (ddC) population pharmacokinetics ; 1993 Jan; 9(1) 503-503

Shelton M, Portmore A, Reichman RC, DeRemer M, Bartos L, Morse GD; Salivary zidovudine concentrations correlation with plasma Pharmacother; 1993 Jan; 13 279-279

O'Donnell MA, Morse GD, Bartos L, Fluman RA; Comparative blood distribution of zidovudine, atevirdine and an ATV metabolite Pharmacother; 1993 Jan; 13 679-679

Reichman R, Demeter L, Fischl M, Para M, Powderly W, Leedom J, Resnick L, Morse GD, Timpone J, Batts D, et al; Phase I study of

atevirdine (ATV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) ; 1993 Jan 159-159

Shelton M, Adams J, Grasela T, Hewitt R, DeRemer M, Morse GD; Zalcitabine (ddC) exposure: lack of impact on CD4 and weight response during combination therapy with zidovudine (ZDV) after previous ZDV therapy ; 1993 Jan 134-134

MORSE GD; Disposition of ATV in ACTG 199 ; 1993 Jan

Letting D, O'Donnell A, DeRemer M, Morse GD; Intracellular zidovudine metabolism in lymphocytes ; 1993 Jan

O'Donnell A, Bartos LC, Beha A, Morse GD; Comparative blood distribution of zidovudine, ATV, and an ATV metabolite ; 1993 Jan

O'Donnell A, Morse GD, Bartos L, Deremer M; In vitro intravascular distribution of a highly plasma protein-bound nonnucleoside reverse transcriptase inhibitor (NNRTI) ; 1993 Jan; 9(1) 502-502

Lee CJ, Morse GD (reviewer); Development and Evaluation of Drugs: From Laboratory through Licensure to Market ; 1993 Jan

Morse GD, Portmore AC, Marder V, Plank C, Olson J, Taylor C, Bonnez W, Reichman RC; Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agents Chemother; 1992 Oct; 36(10) 2245-2252

Morse GD, Portmore AC, Marder V, Plank C, Olson J, Taylor C, Bonnez W, Reichman RC; Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agents Chemother; 1992 Oct; 36(10) 2245-2252

Drusano GL, Yuen GJ, Morse G, Cooley TP, Seidlin M, Lambert JS, Liebman HA, Valentine FT, Dolin R; Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother; 1992 Jun; 36(6) 1280-1283

Shelton MJ, O'Donnell A, Morse GD; Didanosine. Ann Pharmacother; 1992 May; 26(5) 660-670

Amsden GW, Kowalsky SF, Morse GD; Trimetrexate for Pneumocystis carinii pneumonia in patients with AIDS. Ann Pharmacother; 1992 Feb; 26(2) 218-226

MORSE GD; Zidovudine ; 1992 Jan

Morse GD, Hewitt RG, Lawrence W; Granulocyte-Macrophage Colony Stimulating Factor ; 1992 Jan

Hewitt RG, Morse GD; Granulocyte-macrophage colony-stimulating factor and zidovudine in the treatment of neutropenia and human immunodeficiency virus infection. Pharmacotherapy; 1992 Jan; 12(6) 455-461

MORSE GD; Effects of RT Inhibitor and Other HIV Drugs ; 1991 Jan; 1 37-44

MORSE GD; Combination Antiviral Therapy for Human Immunodeficiency Virus Infection ; 1991 Jan 103-103

MORSE GD; Antibiotic ; 1991 Jan

Morse GD, Portmore A, O'Donnell A, Bartos L, Plank C, Reichman RC; Prolonged elimination of zidovudine detected by radioimmunoassay Pharmacother; 1991 Jan; 11 104-104

Morse GD, Hewitt RG, Bartos L, Tousley K, O'Donnell AM, Shelton M, Blair D, Reichman R; Zidovudine assay correlation in patient serum samples RIA vs HPLC Pharmacother; 1991 Jan P-44-P-44

O'Donnell AM, Bartos L, Morse GD; Zidovudine distribution into blood components Pharmacother; 1991 Jan 39-39

Morse GD, Lechner JL, Santora JA, Rozek SL,; Zidovudine update: 1990. DICP; 1990 Aug; 24(7-8) 754-760

Dolin R, Lambert JS, Morse GD, Reichman RC, Plank CS, Reid J, Knupp C, McLaren C, Pettinelli C,; 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis; 1990 Aug; 12 Su S540-S549

Portmore A, Morse GD, Hewitt RG, Reichman R; Comparative oral disposition of zidovudine in Neutropenic AIDS patient and asymptomatic hemophiliacs ; 1990 Jun; 6(3) 196-196

Hewitt RG, Lawrence W, Morse GD, Maliszewski M, Bonnem E; Concurrent administration of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS/ARC ; 1990 Jun; 6(3) 194-194

Lambert JS, Seidlin M, Reichman RC, Plank CS, Lavery M, Morse GD, Knupp C, McLaren C, Pettinelli C, Valentine FT; 2',3'-dideoxyinosine (ddi) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med; 1990 May; 322(19) 1333-1340

Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC; Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother; 1990 Mar; 34(3) 394-397

Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC, Morse ED; Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother; 1990 Mar; 34(3) 394-397

MORSE GD; Current Status of Antiviral Therapy for Human Immunodeficiency Virus Infection ; 1990 Jan; 3 143-148

MORSE GD; Treatment of AIDS ; 1990 Jan

Morse GD, Portmore A, Olson J, Taylor C, Plank C, Reichman RC; Renal excretion of zidovudine and zidovudine-glucuronide during multiple dosing Clin. Pharmacol Ther; 1990 Jan; 47 177-177

Morse GD, Hewitt RG, Reichman RC; Comparative oral disposition of zidovudine in neutropenic AIDS patients and asymptomatic HIV-infected hemophiliacs Pharmacother; 1990 Jan; 10 232-232

Santos P, Morse GD, Korzun W, Venuto RC; Variability of digoxin-like immunoreactive substance among hemodialysis patients. Pharmacother; 1990 Jan; 10 240-240

Karki S, Bentley DW, Luzier A, Taylor C, Morse GD; Cefonicid disposition in geriatric patients with bacterial pneumonia Pharmacother; 1990 Jan; 10 252-252

Morse GD, Ruffino D, Cunningham E, Venuto RC; Reliability of single-dose intraperitoneal vancomycin therapy for gram-positive peritonitis Pharmacother; 1990 Jan; 10 252-252

Morse GD, Hewitt R, Lawrence W, Maliszewski M, Bonnem E, Poeisz B; Zidovudine (ZDV) pharmacokinetics in AIDS patients receiving granulocyte-monocyte colony stimulating factor (GM-CSF) ; 1990 Jan; 6(3) 193-193

Tornatore KM, Morse GD, Jusko WJ, Walshe JJ; Methylprednisolone disposition in renal transplant recipients receiving triple-drug

immunosuppression. Transplantation; 1989 Dec; 48(6) 962-965

Tornatore KM, Morse GD, Jusko WJ, Walshe JJ; Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. Transplantation; 1989 Dec; 48(6) 962-965

Morse GD, Olson J, Portmore A, Taylor C, Plank C, Reichman R; Intravenous and oral pharmacokinetics of zidovudine in hemophilia patients with human immunodeficiency virus infection. Meeting Abstracts ; 1989 Jun; 5 278-278

Morse GD, Olson J, Portmore A, Taylor C, Plank C, Reichman RC; Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. Antiviral Res; 1989 Mar; 11(2) 57-65

Morse GD, Olson J, Portmore A, Taylor C, Plank C, Reichman RC; Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. Antiviral Res; 1989 Mar; 11(2) 57-65

MORSE GD; Pharmacologic Considerations for Zidovudine Therapy in Patients with Human Immunodeficiency Virus Infection ; 1989 Jan; 2 63-68

Walshe JJ, Morse G; Infectious Complications During Peritoneal Dialysis ; 1989 Jan

MORSE GD; Pharmacology Appendix ; 1989 Jan

Morse GD, Holdsworth MT, Walshe JJ; Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. Ther Drug Monit; 1989 Jan; 11(3) 238-245

Morse GD, Holdsworth MT, Venuto R, Gerbasi J, Walshe JJ; Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. Clin Pharmacol Ther; 1988 Dec; 44(6) 654-664

Morse GD, Holdsworth MT, Venuto RC, Gerbasi J, Walshe JJ; Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. Clin Pharmacol Ther; 1988 Dec; 44(6) 654-664

Gutfeld MB, Reddy PV, Morse GD; Vancomycin-associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis. Drug Intell Clin Pharm; 1988 Nov; 22(11) 881-882

Gutfeld MB, Reddy PV, Morse GD, Morse ED; Vancomycin-associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis. Drug Intell Clin Pharm; 1988 Nov; 22(11) 881-882

Tornatore KM, Morse GD, Jusko WJ, Walshe JJ; Methylprednisolone Pharmacokinetics in Renal Transplant Recipients Receiving Cyclosporine ; 1988 Jul

Morse GD, Apicella MA, Walshe JJ; Absorption of intraperitoneal antibiotics. Drug Intell Clin Pharm; 1988 Jan; 22(1) 58-61

Morse GD, Taylor C, Olson J, Reichman RC; Oral zidovudine disposition in hemophiliacs Pharmacother; 1988 Jan 8122-8122

Gutfeld M, Reddy PV, Morse GD; Vancomycin-associated exfoliative dermatitis during continuous ambulatory peritoneal dialysis Drug Int Clin Pharm; 1988 Jan; 11 881-882

Tornatore KM, Morse GD, Jusko WJ, Walshe JJ; Methylprednisolone Pharmacokinetics in Renal Transplant Patients Receiving Cyclosporine Pharmacother; 1988 Jan; 8 138-138

Morse GD, Nairn DK, Walshe JJ,; Once weekly intraperitoneal therapy for gram-positive peritonitis. Am J Kidney Dis; 1987 Oct; 10(4) 300-305

Morse GD, Nairn DK, Bertino JS, Walshe JJ,; Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit; 1987 Jun; 9(2) 212-215

Morse GD, Nairn DK, Bertino JS, Walshe JJ,; Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit; 1987 Jun; 9(2) 212-215

Murray B, Edwards L, Morse G, Kohli RR, Venuto R,; Clinically important interaction of cyclosporine and erythromycin. Transplantation; 1987 Apr; 43(4) 602-604

Morse GD, Lane T, Nairn DK, Deterding J, Curry J, Gal P,; Peritoneal transport of cefonicid. Antimicrob Agents Chemother; 1987 Feb; 31(2) 292-294

Morse GD, Farolino DF, Apicella MA, Walshe JJ,; Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother; 1987 Feb; 31(2) 173-177

Morse GD, Farolino DF, Apicella MA, Walshe JJ,; Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother; 1987 Feb; 31(2) 173-177

Morse GD, Nairn DK, Bertino J, Walshe JJ,; Vancomycin degradation products which crossreact with fluorescence polarization immunoassay during peritoneal dialysis Clin Pharmacol Ther; 1987 Jan; 44 223-223

Morse GD, Apicella MA, Walshe JJ,; Absorption of intraperitoneal antibiotics Clin Pharmacol Ther; 1987 Jan 617-617

MORSE GD; Diuretics ; 1987 Jan

Janicke DM, Morse GD, Apicella MA, Jusko WJ, Walshe JJ,; Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis. Clin Pharmacol Ther; 1986 Aug; 40(2) 209-218

Morse GD, Douglas JB, Upton JH, Rodgers S, Gal P,; Effect of pharmacist intervention on control of resistant hypertension. Am J Hosp Pharm; 1986 Apr; 43(4) 905-909

Walshe JJ, Morse GD, Janicke DM, Apicella MA,; Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin. J Infect Dis; 1986 Apr; 153(4) 796-799

Walshe JJ, Morse GD, Janicke DM, Apicella MA,; Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin. J Infect Dis; 1986 Apr; 153(4) 796-799

Jusko WJ, Morse GD, Janicke DM, Cafarell RF, Apicella MA, Venuto RC, Walshe JJ,; IP Administration of Moxalactam During CAPD Frontiers in Peritoneal Dialysis; 1986 Jan

MORSE GD; Anatomy and Physiology of the Urinary Tract ; 1986 Jan

MORSE GD; Antiinfectives ; 1986 Jan

Morse G, Mathewson M; Pharmacotherapy in Emergency Situations ; 1986 Jan

Morse GD, Rowinski C, Lieveld PE, Walshe JJ; Drug-protein binding during continuous ambulatory peritoneal dialysis. Perit Dial Bull; 1986 Jan; 6(3) 144-147

Morse G, Janicke D, Cafarell R, Piontek K, Apicella M, Jusko WJ, Walshe J; Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther; 1985 Aug; 38(2) 150-156

MORSE GD; Tuberculosis from man to animals. J Lancet; 1985 Apr; 78(4) 138-141

Walshe JJ, Morse GD, Lieveld PA, Venuto RL, Apicella MA; Rationale for an alternative antibiotic therapy based on kinetic analysis and clinical response ; 1985 Jan

MORSE GD; Intraperitoneal cefamandole kinetics in continuous ambulatory peritoneal dialysis patients with and without peritonitis Clin Pharmacol Ther; 1985 Jan; 37 214-214

Morse GD, Janicke DM, Apicella MA, Walshe JJ; Individualization of tobramycin dosing during continuous ambulatory peritoneal dialysis Drug Int. Clin. Pharm; 1985 Jan; 19 469-469

Morse GD, Janicke DM, Cafarell RF, Walshe JJ, Venuto RC, Apicella MA, Jusko WJ; Pharmacokinetics of intraperitoneal moxalactam in CAPD Drug Int Clin Pharm; 1984 Jan; 18 493-493

Morse GD, Janicke DM, Cafarell, Apicella MA, Jusko WJ, Walshe JJ; Intraperitoneal Moxalactam During Continuous Ambulatory Peritoneal Dialysis ; 1984 Jan

MORSE GD; Nursing Pharmacology Videotape Lecture Series - Diuretic Therapy ; 1981 Apr

Smith P, Diczno R, Forrest A, Difrancesco R, Para M, Friedland G, Pollard R, , Morse GD, ACTG 260, ACTG 261; Population Pharmacokinetics of delavirdine and N-Delavirdine in HIV Infection. Clin Pharmacol Ther; 1900 Jan

Frerichs V, Herrmann J, DiCenzo R, Colón LA, Morse GD; The Utilization of Mass Spectrometry in Clinical HIV Antiviral Therapy Management ; 1900 Jan

Frerichs V, Hermann L, Colon LA, Morse GD; Capillary Separations for Characterization of Protease Inhibitor (PI) Protein Binding ; 1900 Jan

**Grants:** [\[click to see more\]](#)

June 2006 to May 2013

NIAID PQA Pharmacology Support Laboratory

Grant Role: Principal Investigator

June 2006 to May 2013

NIAID PQA Pharmacology Support Laboratory QA/QC

Grant Role: Principal Investigator

September 2005 to December 2007

Administrative Supplement Drug Interaction Studies of Buprenorphine and HAART in HIV-Infected Patients

Grant Role: Principal Investigator

June 2005 to May 2009  
UB-UZ AIDS International Training and Research Program  
Grant Role: Principal Investigator

April 2005 to March 2009  
Opioids and HIV Medications: Interactions in Drug Abusers  
Grant Role: Co-Investigator

January 2005 to December 2009  
Post-Doctoral Clinical Pharmacology Training Grant  
Grant Role: Co-Investigator  
Grant Detail: In review

January 2005 to December 2009  
Post-Doctoral Clinical Pharmacology Training Grant  
Grant Role: Principal Investigator  
Grant Detail: In review

June 2004 to May 2007  
International Research Administrative Supplement- Drug Interactions and Antiretrovirals in Resource Poor Countries  
Grant Role: Co-Investigator

January 2004 to December 2005  
Adult AIDS Clinical Trials Group Pharmacology Support Laboratory  
Grant Role: Principal Investigator  
Grant Detail: Social & Scientific Systems, Inc.

November 2003 to October 2006  
Use of TDM to Optimize Anti-AIDS Therapy and Detect Complex Drug-Drug Interactions.  
Grant Role: Co-Investigator  
Grant Detail: To characterize pharmacokinetics (including protein binding and intracellular uptake) of anti-retroviral drugs, in drug abuse and non-abuse AIDS populations, to determine the effects of different combinations of drugs.

November 2003 to October 2006  
Use of TDM to Optimize Anti-AIDS Therapy and Detect Complex Drug-Drug Interactions.  
Grant Role: Principal Investigator  
Grant Detail: To characterize pharmacokinetics (including protein binding and intracellular uptake) of anti-retroviral drugs, in drug abuse and non-abuse AIDS populations, to determine the effects of different combinations of drugs.

October 2003 to October 2005  
Longitudinal Assessment of protease Inhibitors in HIV/HCV/HBV Co-infected Patients  
Grant Role: Co-Investigator

June 2003 to May 2007  
Drug-Drug Interactions and TDM in HIV-Infected Substance Abusers  
Grant Role: Principal Investigator

January 2003 to December 2007  
TDM and Drug interactions in HIV infected substance abusers

Grant Role: Co-Principal Investigator

January 2003 to December 2007

TDM and Drug interactions in HIV infected substance abusers

Grant Role: Co-Principal Investigator

June 2002 to December 2004

HIV ePharmacotherapy Network

Grant Role: Principal Investigator

June 2002 to December 2004

Asthma ePharmacotherapy Network

Grant Role: Principal Investigator

June 2002 to January 1900

National HIV Drug Interactions and TDM Registry

Grant Role: Principal Investigator

January 2002 to December 2003

International Antiretroviral Pharmacology Fellowship

Grant Role: Co-Investigator

Grant Detail: Social & Scientific Systems, Inc.; Supplement to ACTG award

December 2001 to January 1900

National HIV Drug Interactions and TDM Registry

Grant Role: Principal Investigator

August 2001 to January 1900

Clinical Pharmacology Unit

Grant Role: Principal Investigator

January 2001 to December 2004

Adult AIDS Clinical Trials Group Pharmacology Support Laboratory

Grant Role: Co-Investigator

Grant Detail: Social & Scientific Systems, Inc.

January 2001 to December 2004

Adult AIDS Clinical Trials Group Pharmacology Support Laboratory

Grant Role: Principal Investigator

Grant Detail: Social & Scientific Systems, Inc.

September 2000 to October 2001

Development of a UB-Jamestown Pharmacotherapy Information Center

Grant Role: Principal Investigator

June 2000 to June 2002

HIV Pharmacotherapy Network

Grant Role: Principal Investigator

January 2000 to December 2005

Testing Interventions to Improve Adherence to Pharmacological Treatment Regimens

Grant Role: Principal Investigator

Grant Detail: NOT Funded

January 2000 to December 2005

Testing Interventions to Improve Adherence to Pharmacological Treatment Regimens

Grant Role: Co-Investigator

Grant Detail: NOT Funded

January 2000 to December 2004

Supply protocol development, drug assay and data analysis support for the Adult A.I.D.S

Grant Role: Co-Investigator

January 2000 to December 2004

Supply protocol development, drug assay and data analysis support for the Adult A.I.D.S

Grant Role: Principal Investigator

January 2000 to December 2005

Pharmacology Support Laboratory

Grant Role: Co-Investigator

Grant Detail: Supply protocol development, drug assay and data analysis support for the Adult A.I.D.S. Clinical Trial Group

January 2000 to December 2005

Pharmacology Support Laboratory

Grant Role: Principal Investigator

Grant Detail: Supply protocol development, drug assay and data analysis support for the Adult A.I.D.S. Clinical Trial Group

January 2000 to December 2004

Quality Assurance and Quality Control Program

Grant Role: Principal Investigator

Grant Detail: Social and Scientific Systems, Inc.; Supplement to ACTG award

December 1999 to April 2004

Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions with Antiretrovirals in Patients Undergoing Methadone Maintenance

Grant Role: Principal Investigator

February 1998 to December 2000

HIV Pharmacotherapy Network

Grant Role: Principal Investigator

January 1998 to January 2000

Indinavir HPLC and Pharmacokinetic Analysis in ACTG 368 and ACTG 372

Grant Role: Principal Investigator

March 1997 to March 1998

A Phase I Pharmacokinetic Study Comparing 3 Dosing Regimens of Oral Ganciclovir (Maintenance Regimens) and IV Ganciclovir (Induction Regimen) in HIV-Positive Subjects with Varying Degrees of Renal Function

Grant Role: Co-Investigator

November 1996 to November 1997

An Open-Label Study of Delavirdine Mesylate (U-90152T) and Ritonavir Pharmacokinetics in HIV Infected Patients Receiving Both Drugs in Combination

Grant Role: Principal Investigator

August 1996 to January 1997

In Vitro and In Vivo Comparison of Free and Total Cytokine Immunoassay Technologies

Grant Role: Principal Investigator

June 1996 to June 2004

An Evaluation of Cytokines on the Multiple-Dose Pharmacokinetics of Delavirdine Mesylate in Euchlorhydric HIV Positive Patients (M/3331/0048)

Grant Role: Co-Investigator

March 1996 to March 1996

A Double-Blind Randomized, Comparative Study of Delavirdine Mesylate in Combination with Didanosine versus ddI Alone in HIV-1 Infected Individuals with CD4 Counts of <300/mm<sup>3</sup>

Grant Role: Principal Investigator

January 1996 to December 1999

Pharmacology Research Resource Unit

Grant Role: Principal Investigator

June 1995 to June 1997

An Evaluation of the Effect of Glutamic Acid on the Multiple-Dose Pharmacokinetics of Delavirdine Mesylate in Hypochlorhydric and Euchlorhydric HIV-Positive Patients

Grant Role: Principal Investigator

June 1995 to June 1997

An Evaluation of the Influence of Food on Steady-State Delavirdine Mesylate Pharmacokinetics in HIV-1 Infected Patients

Grant Role: Principal Investigator

June 1995 to June 1997

Multiple-Dose Pharmacokinetic Interaction Between Didanosine and Delavirdine in HIV-1 Positive Patients

Grant Role: Principal Investigator

March 1994 to March 1996

ddI Analysis in M/3331/0027

Grant Role: Principal Investigator

March 1994 to March 1996

ZDV Analysis in M/3331/0003

Grant Role: Principal Investigator

March 1994 to March 1996

Pharmacokinetic Monitoring in M/3331/0017 and 0021

Grant Role: Principal Investigator

March 1994 to March 1996  
ACTG 261 Pharmacology Studies  
Grant Role: Principal Investigator

March 1994 to March 1996  
ACTG 260 Pharmacology Studies  
Grant Role: Co-Investigator

July 1993 to July 1994  
Development of a Population Pharmacokinetic Database for Ateviridine and U90125  
Grant Role: Principal Investigator

April 1993 to March 1994  
A Randomized Dose-Escalating Multi-Dose Phase I/II Trial of Oral U87201 Pharmacology Studies  
Grant Role: Principal Investigator

April 1993 to March 1994  
A Phase I Concentration-Targeted Multi-dose Study of Ateviridine Mesylate  
Grant Role: Principal Investigator

March 1993 to February 1994  
Intracellular ddC Concentrations  
Grant Role: Principal Investigator

March 1993 to February 1994  
ddC Population Pharmacokinetics  
Grant Role: Principal Investigator

December 1992 to December 1994  
Gastric Acid Effects on Zidovudine Absorption  
Grant Role: Principal Investigator

November 1992 to December 1995  
Progression of HIV Disease  
Grant Role: Principal Investigator

November 1992 to December 1995  
Blood Distribution of U87201E and U90152  
Grant Role: Principal Investigator

November 1992 to November 1995  
Phase I Pharmacokinetics of IVX-E-59  
Grant Role: Principal Investigator

September 1992 to September 1993  
Pharmacology Lab for U187629 Studies  
Grant Role: Principal Investigator

September 1992 to November 1992

HPLC Assay for IVX-E-59

Grant Role: Principal Investigator

May 1992 to May 1994

Zidovudine and Didanosine Analysis in DATRI 001 and 004

Grant Role: Co-Investigator

March 1992 to February 1994

Population Pharmacokinetics of Antiretrovirals

Grant Role: Principal Investigator

December 1991 to December 1992

Establishment of an Antiretroviral Serum Concentration Database

Grant Role: Principal Investigator

December 1991 to June 1994

HPLC Analysis of U87201

Grant Role: Principal Investigator

December 1991 to June 1994

HPLC Analysis of U901525

Grant Role: Principal Investigator

November 1991 to November 1992

Effect of Food on Zidovudine Bioavailability

Grant Role: Co-Principal Investigator

October 1991 to October 1994

Zidovudine Pharmacokinetics in Women

Grant Role: Principal Investigator

November 1990 to October 1991

Assay Methodology for N<sup>6</sup>-(Isopentenyl) Adenosine in Human Plasma

Grant Role: Principal Investigator

December 1989 to December 1989

Cefonicid Protein Binding in Geriatric and Dialysis Patients

Grant Role: Principal Investigator

August 1989 to August 1992

Development of an AIDS Treatment Evaluation Unit 8/89-8/92

Grant Role: Principal Investigator

Grant Detail: \$59,893 per year subcontract

April 1989 to April 1989

Cost Analysis of the Impact of Pharmacokinetic-Based Antibiotic Regimens on the Treatment of Bacterial Peritonitis in Peritoneal Dialysis Patients

Grant Role: Principal Investigator

September 1988 to September 1988

Development of HPLC Methodology for Dideoxyinosine and D4T in Normal Plasma and Urine and Biologic Samples of Patients with Human Immunodeficiency Virus Infection

Grant Role: Principal Investigator

September 1988 to September 1988

Cefonicid Pharmacokinetics in Geriatric Patients with Bacterial Pneumonia

Grant Role: Principal Investigator

January 1988 to December 1990

Development of a Regional AIDS Education and Training Center in New York State and Pennsylvania

Grant Role: Co-Investigator

Grant Detail: \$72,500/year, \$15,000 WNY

September 1986 to September 1986

Cefonicid Protein Binding in End-Stage Renal Disease Patients

Grant Role: Principal Investigator

September 1986 to September 1986

Vancomycin Protein Binding in Hemodialysis Patients

Grant Role: Principal Investigator

August 1986 to August 1989

Development of an AIDS Treatment Evaluation Unit

March 1986 to March 1986

Individualization of Cyclosporine Dosing and Absorption Studies

Grant Role: Co-Principal Investigator

November 1985 to November 1985

Cyclosporine-Methylprednisolone Interaction in Renal Transplant Patients

Grant Role: Co-Principal Investigator

August 1985 to August 1985

Vancomycin Protein Binding in CAPD Patients

Grant Role: Principal Investigator

July 1985 to July 1985

Cefonicid Pharmacokinetics in CAPD Patients

Grant Role: Co-Investigator

May 1985 to May 1985

Vancomycin Pharmacokinetics in CAPD Patients

Grant Role: Co-Principal Investigator

April 1984 to April 1984

Cefamandole Protein Binding and Bacterial Activity During CAPD

Grant Role: Principal Investigator

September 1983 to September 1983

Cefamandole, Moxalactam and Tobramycin Pharmacokinetics in Non-infected CAPD Patients

Grant Role: Co-Investigator

September 1983 to September 1983

Cefamandole Pharmacokinetics and Clinical Efficacy Utilizing a Single Daily Intraperitoneal Dose

Grant Role: Co-Investigator

January 1900 to January 1900

Opportunities for Health Center to Implement Comprehensive submitted Pharmaceutical Care Services

Grant Role: Principal Investigator

January 1900 to January 1900

Fogarty AIDS Treatment and Research Post-Doctoral Training Grant

Grant Role: Co-Investigator

Grant Detail: In Review

January 1900 to January 1900

Clinical Research Curriculum Award

Grant Role: Co-Investigator

Grant Detail: In Review

January 1900 to January 1900

Clinical Research Career Development

Grant Role: Co-Investigator

Grant Detail: In Review

January 1900 to January 1900

Biomedical Computing Research Center

Grant Role: Co-Investigator

Grant Detail: In review

January 1900 to January 1900

Pharmacokinetics of Zidovudine and Dideoxyinosine in ACTG 143

Grant Role: Co-Investigator

January 1900 to January 1900

An Evaluation of the Multiple-Dose Pharmacokinetics of Delavirdine Mesylate in Hypochlorhydric and Euchlorhydric HIV-Positive Patients

Grant Role: Principal Investigator

January 1900 to January 1900

A Double-Blind Randomized, Dose-Response Study of Delavirdine Mesylate in Combination with Zidovudine versus ZDV Alone in HIV-1 Infected Individuals with CD4 Counts of 200-500/mm<sup>3</sup>

Grant Role: Principal Investigator

January 1900 to January 1900

Open Label, Extended Use Study of Delavirdine Mesylate in HIV+ Patients Who Participated in Multiple Dose Pharmacokinetic/Drug

Interaction Study

Grant Role: Principal Investigator

January 1900 to January 1900

Fogerty Training Grant

Grant Role: Co-Investigator

Grant Detail: A supplemental application to the UC Berkeley AITRP, based at SUNY-Buffalo in collaboration with the University of Zimbabwe, to develop and support post-doctoral fellowship and pre-doctoral training and development of a clinical research resource, based in Harare, Zimbabwe, but benefiting the other South African countries as well.

January 1900 to January 1900

Fogerty Training Grant

Grant Role: Co-Principal Investigator

Grant Detail: A supplemental application to the UC Berkeley AITRP, based at SUNY-Buffalo in collaboration with the University of Zimbabwe, to develop and support post-doctoral fellowship and pre-doctoral training and development of a clinical research resource, based in Harare, Zimbabwe, but benefiting the other South African countries as well.

January 1900 to January 1900

Opportunities for Health Center to Implement Comprehensive submitted Pharmaceutical Care Services

Grant Role: Co-Investigator

January 1900 to January 1900

Fogarty AIDS Treatment and Research Post-Doctoral Training Grant.

Grant Role: Principal Investigator